Patent application number | Description | Published |
20100022535 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors - 2-pyridyl-substituted imidazoles which are used advantageously in the treatment of diseases mediated by ALK 5 or ALK 4 inhibitors or both. | 01-28-2010 |
20120128807 | COMPOSITION FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME - The present invention relates to a composition or a method for treating or preventing irritable bowel syndrome. The present invention uses | 05-24-2012 |
20130018052 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS - The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal. | 01-17-2013 |
20130030174 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR - Disclosed is a composition effective in reducing skin wrinkles. The composition comprises or uses a phosphodiesterase 5 (PDE5) inhibitor as an active ingredient. Further disclosed is a method for reducing skin wrinkles using the composition. | 01-31-2013 |
20130183741 | MDCK-DERIVED CELL LINES ADAPTED TO SERUM-FREE CULTURE AND SUSPENSION CULTURE AND METHOD FOR PREPARING VACCINE VIRUS USING THE CELLS - Disclosed is a Madin-Darby canine kidney (MDCK)-derived cell line. The MDCK-derived cell line is derived from MDCK cells deposited under accession number ATCC CCL-34. The MDCK-derived cell line can be prepared by serum-free culture and suspension culture. Preferably, the MDCK-derived cell line has low or no tumorigenicity. The MDCK-derived cell line is preferably selected from MDCK Sky1023, MDCK Sky10234 and MDCK Sky3851. Further disclosed are a culture method for growing the MDCK-derived cells and a method for producing a vaccine virus using the MDCK-derived cells. | 07-18-2013 |
20130224257 | METHOD FOR PREPARING MICROSPHERES AND MICROSPHERES PRODUCED THEREBY - The present invention relates to a method for preparing microsphere and microspheres produced thereby. The method comprises: mixing a water-insoluble organic solvent with a dispersion solvent; mixing a polymer compound, a drug and a water-insoluble organic solvent to prepare a dispersed phase; mixing the dispersed phase with the dispersion solvent mixed with the water-insoluble organic solvent to prepare an emulsion; and adding a base or an acid to the prepared emulsion. With the method, it is possible to prepare a drug-containing polymeric microsphere cost-effectively and conveniently. | 08-29-2013 |
20130296534 | FUSION PROTEIN HAVING FACTOR IX ACTIVITY - Disclosed is a fusion protein comprising blood coagulation factor IX (FIX) and transferrin. The fusion protein exhibits improved specific FIX activity, as compared to native FIX, and can be useful in the treatment of FIX deficiency-associated diseases. | 11-07-2013 |
20140072531 | METHOD FOR PREPARING MICROPARTICLES WITH REDUCED INITIAL BURST AND MICROPARTICLES PREPARED THEREBY - A method for preparing polymer microparticles with a reduced initial burst, and the polymer microparticles prepared thereby, the method including: contacting polymer microparticles with an alcohol aqueous solution, the polymer microparticles prepared thereby, and use for drug delivery of the polymer microparticles. | 03-13-2014 |
20140179701 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR - Disclosed is a composition effective in reducing skin wrinkles. The composition comprises or uses a phosphodiesterase 5 (PDE5) inhibitor as an active ingredient. Further disclosed is a method for reducing skin wrinkles using the composition. | 06-26-2014 |
20140187775 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR - Disclosed is a composition effective in reducing skin wrinkles. The composition comprises a phosphodiesterase 5 (PDE5) inhibitor, preferably the compound of chemical formula 1, more preferably, mirodenafil as an active ingredient. Further disclosed is a method for reducing skin wrinkles using the composition. | 07-03-2014 |
20140194501 | COMPOSITION FOR EYELASH GROWTH - The present invention relates to a pharmaceutical or cosmetic composition and a method for promoting eyelash growth, wherein nipradilol or pharmaceutically or cosmetically acceptable salts thereof are used as active ingredients. The composition of the invention may comprise prostaglandin F2α analogues. | 07-10-2014 |
20140213647 | COMPOUND USEFUL FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME AND COMPOSITION INCLUDING SAME - The present invention provides a compound of formula (I) or a prodrug thereof useful for treating or preventing irritable bowel syndrome, and a composition comprising the compound as an active ingredient. Also, the present invention provides a method for treating or preventing irritable bowel syndrome, which comprises administrating a therapeutically or prophylactically effective amount of the compound or the composition to a subject in need of treating or preventing irritable bowel syndrome. | 07-31-2014 |
20140312382 | POWER DEVICE AND METHOD OF MANUFACTURING THE SAME - Provided are a power device having an improved field stop layer and a method of manufacturing the same. The power device includes: a first field stop layer formed of a semiconductor substrate and of a first conductive type; a second field stop layer formed on the first field stop layer and of the first conductive type, the second field stop layer having a region with an impurity concentration higher than the first field stop layer; a drift region formed on the second field stop layer and of the first conductive type, the drift region having an impurity concentration lower than the first field stop layer; a plurality of power device cells formed on the drift region; and a collector region formed below the first field stop layer, wherein the second field stop layer includes a first region having a first impurity concentration and a second region having a second impurity concentration higher than the first impurity concentration. | 10-23-2014 |
20150045749 | PERCUTANEOUS ABSORPTION PREPARATION CONTAINING DONEPEZIL, AND METHOD FOR PREPARING SAME - Provided is a transdermal delivery system (for example, in the form of a patch) having a double-layer structure including a drug-containing matrix layer and an adhesive layer, wherein the drug-containing matrix layer is obtained by completely dissolving donepezil using a certain polymer and then formulating along with an adhesive; and a process for preparing the same. The transdermal delivery system according to the present invention does not show any crystallization of donepezil in the formulation, can release donepezil at a uniform rate for a long time, and can inhibit the release dumping phenomenon that occurs in a transdermal delivery system having a single-layer structure. | 02-12-2015 |